EDUCATIONAL NOTICE: Peptidings provides information for educational and research purposes only. The compounds discussed on this page are subjects of ongoing scientific investigation at varying stages of development. None of the information presented here constitutes medical advice or a recommendation for use. Consult a qualified healthcare provider before making any decisions about peptide use.
Browse by Condition
Menopause & Perimenopause
Menopause is the condition where the peptides on Peptidings are most medically established—and where the distinction between treatment and research matters most. Seven of the eight compounds here are FDA-approved drugs prescribed by reproductive endocrinologists every day. They are not experimental. They are not biohacker favorites. They are the standard of care for managing the hormonal cascade that defines menopause and perimenopause.
What makes this condition page editorially important is the context. These compounds act on the hypothalamic-pituitary-gonadal (HPG) axis—the hormonal chain of command that shifts dramatically during perimenopause and shuts down at menopause. Understanding where each compound enters that cascade explains why an IVF drug (HMG), four GnRH analogs, a labor-induction drug (Oxytocin), and a sexual-desire drug (PT-141) all appear on the same condition page. Evidence tiers reflect what each compound has demonstrated specifically for menopause-related indications.
Condition at a Glance
|
8 Compounds Researched |
7 FDA Approved |
1 Clinical Trials |
8 With Human Data |
|
Approved Drug FDA-approved or equivalent regulatory approval |
Clinical Trials Human clinical trial data (Phase I+) |
BLUF: Bottom Line Up Front
Seven of eight compounds here are FDA-approved drugs with decades of clinical data—though not all are approved specifically for menopause. HMG is the workhorse: the standard of care for ovarian stimulation in women pursuing fertility during perimenopause. The GnRH analogs (Leuprolide, Nafarelin, Triptorelin, Gonadorelin) manage endometriosis, uterine fibroids, and hormonal regulation—conditions that peak in the perimenopausal transition. Oxytocin has emerging research on bone density preservation relevant to postmenopausal osteoporosis, beyond its established role in labor. PT-141 addresses hypoactive sexual desire disorder, which affects up to 40% of postmenopausal women. Kisspeptin-10 is the pipeline compound—Phase 2 IVF data with zero ovarian hyperstimulation risk, potentially transformative for perimenopausal fertility support.
Compounds Researched for This Condition
8 compounds with published research relevant to menopause & perimenopause. Evidence tiers reflect the strength of research for this specific condition—not the compound’s highest overall tier.
Group 1 of 3
The Fertility Support
Compounds that directly support reproductive function during the perimenopausal transition—when fertility declines but has not yet ended.
Group 2 of 3
The GnRH Analogs
Four FDA-approved GnRH analogs that suppress or stimulate the HPG axis—used to treat the estrogen-dependent conditions that peak in perimenopause and for cycle control in IVF protocols.
|
|
|
||||||||||||
|
Group 3 of 3
The Postmenopausal Quality of Life
Compounds addressing the symptoms and health consequences that persist after menopause—sexual health and the broader impact of estrogen withdrawal.
|
|
What the Research Landscape Looks Like
The compounds on this page act at different levels of the HPG axis—the hormonal cascade that controls reproduction and undergoes dramatic change during perimenopause before shutting down at menopause. Kisspeptin-10 sits at the top, triggering GnRH release from the hypothalamus. The GnRH analogs (Leuprolide, Nafarelin, Triptorelin, Gonadorelin) act on GnRH receptors in the pituitary—some to stimulate, most through continuous-stimulation desensitization that paradoxically suppresses the downstream cascade. HMG replaces the gonadotropins (FSH and LH) that the pituitary normally releases. Understanding where each compound enters this cascade explains why drugs developed for entirely different purposes converge on the same condition page.
The clinical reality of menopause peptides is that most women will encounter these compounds through their reproductive endocrinologist or gynecologist, not through self-administration. HMG, the GnRH analogs, PT-141, and therapeutic Oxytocin are prescribed medications used in clinical protocols. Kisspeptin-10 is administered in research settings. Gonadorelin has specific diagnostic applications. This is not a self-experimentation condition page—it is a medical treatment landscape, and the compounds listed here are tools in an established clinical toolkit for the hormonal realities of this life stage.
| Mechanism | Compounds |
|
HPG Axis Stimulation Directly activating the reproductive hormone cascade—providing the gonadotropins or triggering their release to support ovarian function during the perimenopausal decline. |
HMG, Kisspeptin-10, Gonadorelin |
|
GnRH Receptor Desensitization Continuously overstimulating GnRH receptors to paradoxically suppress the reproductive axis—used therapeutically to manage estrogen-dependent conditions like endometriosis and fibroids that peak in perimenopause. |
Leuprolide, Nafarelin, Triptorelin |
|
Central Nervous System—Sexual Desire Activating melanocortin-4 receptors in the brain to modulate sexual desire through central pathways—independent of peripheral estrogen levels. |
PT-141 (Bremelanotide) |
|
Bone Metabolism / Osteoblast Signaling Acting on bone cells through oxytocin receptors to influence the balance between bone formation and resorption—relevant to postmenopausal osteoporosis risk. |
Oxytocin |
Plain English
Eight compounds, two phases of menopause. For perimenopause—when fertility is declining but not gone—HMG provides the hormones your ovaries need to respond, the GnRH analogs (Leuprolide, Nafarelin, Triptorelin, Gonadorelin) manage conditions like endometriosis that flare during the transition and shut down cycles for IVF, and Kisspeptin-10 is the pipeline drug that could make fertility treatment safer. For postmenopause—when estrogen has withdrawn and its consequences set in—PT-141 addresses the sexual desire changes that affect nearly half of postmenopausal women, and Oxytocin may play a role in bone density that goes beyond its famous reputation as the ‘love hormone.’ These are mostly prescribed medications, not self-administered peptides.
Related Research
Research Clusters Covering These Compounds
|
Sexual Health & Hormonal Peptides The primary cluster—all eight compounds originate here, covering the full HPG axis from hypothalamus to target tissues. |
Disclaimer: This page is for educational and research purposes only. It does not constitute medical advice, diagnosis, or treatment. The compounds discussed are subjects of ongoing scientific research and have not been evaluated by the FDA for all applications described. Consult a qualified healthcare provider before making any decisions about your health.